MarketCap
Facebook
X
TelegramGeschäftsbericht 2022
hinzugefügt 23.12.2023
HEXO Corp. Betriebsaufwand 2011-2026 | HEXO
Betriebsaufwand Jährlich HEXO Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 106 M | 111 M | 24.4 M | 7.93 M | - | - | - | - | - | - |
Alle Zahlen in CAD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 111 M | 7.93 M | 62.4 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 15.13 | 8.04 % | $ 96.9 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 0.94 | -2.4 % | $ 101 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.26 | -1.48 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
154 M | $ 2.51 | -0.6 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 7.92 | -1.61 % | $ 406 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 22.55 | -0.44 % | $ 1.04 B | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.01 | -1.31 % | $ 42.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 6.17 | 5.29 % | $ 244 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 1.05 | 2.94 % | $ 24.5 M | USA |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 4.98 | -2.35 % | $ 1.82 B | Canada |
 |
Solid Biosciences
SLDB
|
179 M | $ 6.9 | -3.22 % | $ 604 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.35 | -1.1 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.4 | -5.88 % | $ 2.98 M | USA |
 |
Harrow Health
HROW
|
174 M | $ 34.38 | 1.1 % | $ 1.26 B | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
1.52 B | $ 6.33 | -1.86 % | $ 3.91 B | Canada |
 |
Evolus
EOLS
|
107 M | $ 4.48 | -4.27 % | $ 289 M | USA |
 |
Veru
VERU
|
44 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Viatris
VTRS
|
5.67 B | $ 13.33 | 0.26 % | $ 16 B | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 0.9 | 2.51 % | $ 44.9 M | USA |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 2.31 | - | $ 24.1 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
2.62 B | $ 9.57 | - | $ 1.33 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 0.77 | 1.31 % | $ 3.32 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |